某院抗肿瘤药静脉输液过程调查分析

目的：调查某院抗肿瘤静脉输液过程，为制定某院抗肿瘤药静脉输液管理规范奠定基础。方法：收集某院2015年10月-2016年1月肿瘤科及放疗科住院化疗患者共1 093袋抗肿瘤药静脉输液信息，就给药顺序、预处理时机、滴注时间、冲管、稳定性、水化等方面进行汇总分析。结果：仅有1例联合用药顺序错误；预处理时机达标情况为紫杉醇脂质体43.29%、多西他赛100%；滴注时间达标情况为紫杉醇脂质体14.20%、多西他赛2.26%、奥沙利铂85.82%、奈达铂99.59%、依托泊苷100%、伊立替康38.64%、培美曲塞100%、吉西他滨13.04%；冲管达标情况为紫杉醇脂质体20.45%、多西他赛8.47%、奥沙利铂5.22%、奈达铂19.50%、伊立替康0%、培美曲塞14.59%、吉西他滨0%；多西他赛成品输液在4 h内用完的占40%；奈达铂输液结束后继续点滴输液量达1 000 mL以上的占47.58%。结论：某院抗肿瘤药静脉输液过程中还存在一定不足之处，需要医、药、护三方共同协作，制定管理规范。

Analysis of intravenous transfusion of antineoplastic agents in a hospital

OBJECTIVE To formulate the management regulation on intravenous transfusion of antineoplastic agents in a hospital by investigating and analyzing intravenous transfusion of antineoplastic agents.METHODS Transfusion information of 1 093 bags of antineoplastic agents were collected from patients in departments of oncology and radiotherapy from October 2015 to January 2016,and analyzed for treatment sequence,pretreated time,infusion time,flush,stability and hydration.RESULTS Only one case of sequence error was found,in which antineoplastic agents were used in combination.The compliance of pretreated time was 43.29% for liposomal paclitaxel,100% for docetaxel.The compliance of infusion time was 14.20% for liposomal paclitaxel,2.26% for docetaxel,85.82% for oxaliplatin,99.59% for nedaplatin,100% for etoposide,38.64% for irinotecan,100% for pemetrexed,13.04% for gemcitabine.The compliance of flush was 20.45% for liposomal paclitaxel,8.47% for docetaxel,5.22% for oxaliplatin,19.50% for nedaplatin,0% for irinotecan,14.59% for pemetrexed,0% for gemcitabine.For docetaxel,40% was infused within 4 hours.After transfusion of nedaplatin,47.58% patients continued to receive over 1000ml intravenous rehydration.CONCLUSION Some deficiencies exist during intravenous infusions of antineoplastic agents.It is necessary to formulate the management regulation for intravenous infusions for antineoplastic agents by cooperation between doctors,nurses and pharmacists.